Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study

AIM: To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. METHODS: Medical records of patients with psoriasis treated with biological agents at the Departmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamer, Funda, Avcı, Emine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480757/
https://www.ncbi.nlm.nih.gov/pubmed/32881431
http://dx.doi.org/10.3325/cmj.2020.61.333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480757/
https://www.ncbi.nlm.nih.gov/pubmed/32881431
http://dx.doi.org/10.3325/cmj.2020.61.333

Ejemplares similares